Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Leading Vaccine Developer, Sinovac, Aims To Channel Expanding Earnings Into Acquisitions

This article was originally published in PharmAsia News

Executive Summary

BEIJING - While reporting a steep rise in profits for the second quarter of this year, the leadership of Chinese vaccine developer Sinovac Biotech said the cash-rich outfit is screening potential acquisition candidates across China

You may also be interested in...



Vaccine Maker Sinovac Enters Into Joint Venture In Chinese Coastal City Of Dalian

SHANGHAI - Flush with cash following strong earnings for the third quarter and rising sales of the seasonal influenza vaccine Anflu, Beijing-based Sinovac Biotech aims to expand operations by investing in a joint venture in the Northeastern coastal city of Dalian, the company announced Nov. 25

Vaccine Maker Sinovac Enters Into Joint Venture In Chinese Coastal City Of Dalian

SHANGHAI - Flush with cash following strong earnings for the third quarter and rising sales of the seasonal influenza vaccine Anflu, Beijing-based Sinovac Biotech aims to expand operations by investing in a joint venture in the Northeastern coastal city of Dalian, the company announced Nov. 25

China's Sinovac, With High-level Government Backing, Could Win Global Race To Market A/H1N1 Vaccine

BEIJING - With the strong support of China's central government and Beijing health authorities, leading vaccine maker Sinovac Biotech could become the first to cross the finish line in the worldwide race to produce a defense to the A/H1N1 pandemic

Related Content

UsernamePublicRestriction

Register

SC072538

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel